Revenio Group Corporation: Managers' transactions
| Revenio Group Corporation, Managers' transactions, June 21, 2017 at 16:30 Revenio Group Corporation: Managers' transactions Person subject to the notification requirement | ||
| Name: | Sundell, Ann-Christine | |
| Position: | Member of the Board/Deputy member | |
| Initial Notification | ||
| Reference number: | 743700I27E0FWSXLKK04_20170620104702_5 | |
| Issuer | ||
| Name: | Revenio Group Oyj | |
| LEI: | 743700I27E0FWSXLKK04 | |
| Transaction details | ||
| Transaction date: | 2017-06-21 | |
| Nature of the transaction: | Receipt of a Share-Based Incentive or Remuneration | |
| Instrument: | Share | |
| ISIN: | FI0009010912 | |
| Volume: | 250 | |
| Unit price: | 0,00000 Euro | |
| Aggregated transactions | ||
| Volume: | 250 | |
| Volume weighted average price: | 0.00000 Euro | |
For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932
Distribution:
Nasdaq Helsinki
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki.